FDA cancels vaccine advisory meeting for choosing flu strains for next season’s shots

FDA cancels vaccine advisory meeting for choosing flu strains for next season’s shots


FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. 

Jason Reed | Reuters

A crucial March meeting of vaccine advisors to the Food and Drug Administration has been canceled without explanation, a member of the advisory panel told CNBC on Wednesday. 

The meeting of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, is held every March to select flu strains for shots released in the upcoming fall and winter. 

But Dr. Paul Offit, a member of that panel, told CNBC that he received an email at 4:18 p.m. ET on Wednesday saying that the upcoming March 13 meeting is canceled. He said there was no indication of whether it will be rescheduled.

“Who canceled this meeting? Why did they cancel the meeting? Will manufacturers now turn to the World Health Organization to determine strains for this year’s influenza vaccines?” Offit told CNBC. 

The Department of Health and Human Services did not immediately respond to a request for comment.

The canceled meeting comes as Robert F. Kennedy Jr., who now leads HHS, makes early moves that could affect vaccination uptake and policy in the U.S. Kennedy has a lengthy track record of being a vaccine skeptic. 

It also comes amid a particularly brutal flu season in the U.S. CDC data shows the flu has caused up to an estimated 910,000 hospitalizations since October, which puts the season on track to be the most severe in at least a decade.

Earlier this month, a separate meeting of advisors who help the Centers for Disease Control and Prevention make recommendations for vaccines was postponed to “accommodate public comment in advance of the meeting,” several news outlets reported. It is also unclear if that meeting will be rescheduled. 

Kennedy also said last week that he will review the childhood vaccine schedule despite earlier pledges not to do so. He promised that a new “Make America Healthy Again” commission would investigate vaccines, pesticides and antidepressants to see if they have contributed to a rise of chronic illness in the U.S.

Meanwhile, the Trump administration is weighing pulling funding for Moderna’s bird flu vaccine, Bloomberg reported on Wednesday.

The country is grappling with a record-breaking bird flu outbreak that’s impacted dozens of cattle herds along with poultry flocks, which has sent egg prices skyrocketing. Its rapid spread in animals has raised concerns about broader spread to humans.”



Source

DuPont prepares to say goodbye to electronics. What investors get with the remaining company
Health

DuPont prepares to say goodbye to electronics. What investors get with the remaining company

Earlier in the week, we looked at the upcoming DuPont electronics business spinoff and what investors are getting with the new Qnity Electronics, which has a strong foothold in the semiconductor industry. Now, here is a look at what will be left of the new DuPont after the planned Nov. 1 split and the stocks […]

Read More
Abbott’s quarter disappoints again: We’re downgrading it and considering what to do next
Health

Abbott’s quarter disappoints again: We’re downgrading it and considering what to do next

Shares of Abbott Laboratories fell 3% on Wednesday after the diversified health-care company delivered another less-than-stellar quarter. Revenue in the third quarter ended Sept. 30 rose 6.9% to $11.37 billion, missing the $11.4 billion consensus estimate compiled by market data provider LSEG. Organic sales , excluding Covid testing results, rose 7.5%, beating the 5.9% estimate, […]

Read More
Higher education CEO on AI’s growing role in health-care degree market
Health

Higher education CEO on AI’s growing role in health-care degree market

AI is quickly transforming the way companies and CEOs are approaching their businesses and the strategies that take them forward. Amid that rapid transformation, Adtalem Global Education CEO Steve Beard said there is a “threshold question” that he keeps coming back to. “That question is, is AI a complement for what you do, or is […]

Read More